<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>150-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of cyproterone with risk of lower contraceptive effectiveness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>--in its use as a hormonal contraceptive. Use a reliable contraceptive method, additional or alternative, during the length of the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>150-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyproterone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In its indications as an anti-androgen, clinical monitoring and if possible adjustment of the dosage of the cyproterone during the administration with the bosentan and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>150-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyproterone</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-for its use as a hormonal contraceptive: use another method of contraception in particular a barrier type, during the length of the administration of these substances together and a cycle following</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>150-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyproterone</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-in its use as a hormonal contraceptive: use instead another method of contraception in particular a barrier type, during the length of the administration of these substances together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>150-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyproterone, due to increase of its hepatic metabolism by the St Johns Wort </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>150-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PERAMPANEL" rxcui="1356552">
<ATC code="N03AX2" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of perampenel &gt;or = to 12 mg/day, risk of decrease of the effectiveness of the cyproterone.</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>In its use as a hormonal contraceptive: use instead another method of contraception in particular a barrier type, during the length of the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>150-CYPROTERONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HB01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of antagonism of the progestin effects</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Do not take a progestin treatment fewer than 12 hours after the ulipristal is stopped.</COMMENT>
</INTERACTION>
</INTERACTIONS>
